Founded on March 28, 1995 with a vision of creating a healthier China, we have rapidly evolved from a distributor of pharmaceutical products into a leading manufacturer and supplier of drugs in the rapidly growing China pharmaceutical market. We currently have five Good Manufacturing Practices("GMP")-certified modernized manufacturing bases, two nationwide sales and marketing subsidiaries, one research and development center and total of more than 2,000 employees.

We currently manufacture and sell more than 50 pharmaceutical products and are the exclusive distributor of three additional pharmaceutical products marketed under our brand name, covering a wide range of diseases such as cancer, cerebrovascular and cardiovascular diseases, infections, arthritis, diarrhea, allergies, respiratory conditions and urinary conditions. Our market leading pharmaceutical products include a stroke management medication, Bicun, the first synthetic free radical scavenger (edaravone injection) sold in China; Zailin, a generic amoxicillin granule antibiotic; an innovative anti-cancer medication, Endu (also known as “Endostar”), the first recombinant human endostatin injection approved for sale in China; Yingtaiqing, a generic diclofenac sodium sustained-release capsule for inflammation and pain relief; Anqi, a generic amoxicillin with clavulanate potassium antibiotic; and Biqi, an OTC generic smectite powder for diarrhea. These products contributed annual revenue of more than RMB 800 million in 2006. In addition to these core products, Simcere Kechuanning, Zaike, and Faneng each contributed annual revenue of RMB 30 - 40 million in 2006. In addition, China’s State Food and Drug Administration ("SFDA") has also granted us approval for the manufacture and sale of 100 other products.

Our strategic focus is to introduce first-to-market generic and innovative pharmaceuticals for the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy, such as our first-to-market generic stroke management medication Bicun and our anti-cancer medication Endu (also known as “Endostar”).

In September 2006, Simcere acquired 80% of Shandong Simcere Medgenn Bio-Pharmaceutical Co., Ltd for RMB 200 million and launched its new patented anti-cancer drug, Endu (also known as "Endostar"), the first recombinant human endostatin successfully commercialized in the world. This purchase was one of the biggest acquisition cases in China’s pharmaceutical industry targeting a single pharmaceutical product’s intellectual property. The successful commercialization of Endu is a result of joint efforts from our R&D team, led by Dr. Yongzhang Luo, the independent clinical research team, headed by Dr. Yan Sun, and our professional sales and marketing team. Clinical research was conducted in 24 hospitals in China and an independent specialists committee audited the clinical research statistics and data. The results of our Phase III clinical trial on 493 non-small-cell lung cancer ("NSCLC") patients showed that the Endu-plus-chemotherapy approach provides an effective alternative for treating NSCLC.

Our goal is to become a leading pharmaceutical company by providing innovative medicine in China. We believe constant innovation in research and development is vital to our long-term competitiveness and success and will determine the future of the pharmaceutical industry in China. We will maintain our commitment to investing in research and development activities while focusing on innovative products with a high potential for commercialization, as well as first-to-market generic pharmaceutical products. Our over 5,000m2 research and development center in Nanjing provides a solid platform to support a variety of research activities including synthetic research, drug analysis and pharmacological and cytological research. Our post-doctorate research workstation currently has four research staff and it was certified by the State Ministry of Human Resources. To supplement our in-house research and development capabilities, we also plan to increase our collaborations with domestic and international pharmaceutical and biotechnology companies and institutions. Our agreement with Tsinghua University in February 2006 established a Joint Laboratory for Drug Discovery to engage in the research and development of innovative pharmaceuticals. Simcere’s commitment to research and development helps to ensure a robust pipeline of product candidates in various stages of development, including products for the treatment of cancer, cerebrovascular diseases, infections, rheumatoid arthritis, nasal allergies and nausea and vomiting associated with chemotherapy. With our deep knowledge about the Chinese pharmaceutical market and increasing cooperation with domestic and international resources, Simcere is well positioned to provide quality products and services that will exceed our customers’ expectations and help us meet the challenges of the new century.

Our employees are valuable business partners and internal customers, sharing our beliefs and business vision. Simcere believes every employee’s potential should be maximized and we are devoted to investing our resources to ensure their success. A hunger for excellence is in the blood of every Simcere employee and they strive to create value for the company to maximize our shareholders’ return while being socially responsible.